2002
DOI: 10.1016/s0168-8278(02)00025-9
|View full text |Cite
|
Sign up to set email alerts
|

The role of endogenous heme oxygenase in the initiation of liver injury following limb ischemia/reperfusion

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
13
0

Year Published

2004
2004
2024
2024

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 21 publications
(14 citation statements)
references
References 20 publications
1
13
0
Order By: Relevance
“…Using intravital video microscopy, we showed that induction of heme oxygenase (HO-1), the rate-limiting enzyme in the catabolism of heme into carbon monoxide (CO), biliverdin, and free iron (7), prevented hepatocellular death, microvascular perfusion deficits, and inflammation that results following hind limb ischemia/reperfusion (I/R) (8)(9)(10)(11)(12). It is now generally accepted that increased HO activity is protective in several models of hepatic stress.…”
mentioning
confidence: 99%
“…Using intravital video microscopy, we showed that induction of heme oxygenase (HO-1), the rate-limiting enzyme in the catabolism of heme into carbon monoxide (CO), biliverdin, and free iron (7), prevented hepatocellular death, microvascular perfusion deficits, and inflammation that results following hind limb ischemia/reperfusion (I/R) (8)(9)(10)(11)(12). It is now generally accepted that increased HO activity is protective in several models of hepatic stress.…”
mentioning
confidence: 99%
“…They demonstrate that a single administration of this vector several weeks in advance of ischemia/reperfusion injury to multiple tissues such as heart, liver, and skeletal muscle yields rapid and timely induction of hHO-1 during ischemia that resulted in dramatic reduction in tissue damage. They selected the HO-1 as a therapeutic target from among many other potential therapeutic genes, such as superoxide dismutase [50], nitric oxide synthase [51], and vascular endothelial growth factor [52] on the basis of its documented cytoprotective effects [53] for the purpose of demonstrating the feasibility and therapeutic potential of this strategy with a validated cardioprotective gene. However, they emphasize that this strategy can be extended to the expression of any gene or combination of gene(s) with therapeutic value for protection from ischemia-induced injury.…”
Section: Discussionmentioning
confidence: 99%
“…In addition, given the widespread tropism of AAV (23) and its capability for long-term expression of therapeutic genes, the prevalence of hypoxia as a principal trigger of injury in diverse tissues, the ubiquitous distribution of hypoxia-inducible factor 1␣ (24,25), and the effectiveness of HO-1 in mediating tissue protection from I͞R injury, this approach is generally applicable to a variety of tissues that may undergo I͞R injury, such as the kidneys, lungs, liver, and brain. The selection of HO-1 as a therapeutic target from among many other potential therapeutic genes, such as superoxide dismutase (26), nitric oxide synthase (27,28), and vascular endothelial growth factor (29), was made on the basis of its documented cytoprotective effects (30,31) for the purpose of demonstrating the feasibility and therapeutic potential of this strategy with a validated cardioprotective gene. However, we emphasize that this strategy can be extended to the expression of any gene or combination of gene(s) with therapeutic value for protection from ischemia-induced injury.…”
Section: Discussionmentioning
confidence: 99%